These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 34148378)
1. KRAS-targeted therapies in advanced solid cancers: drug the undruggable? Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378 [No Abstract] [Full Text] [Related]
2. KRAS Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176 [TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib. Mausey N; Halford Z Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573 [TBL] [Abstract][Full Text] [Related]
4. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib? Oya Y; Imaizumi K; Mitsudomi T Lung Cancer; 2024 Aug; 194():107886. PubMed ID: 39047616 [TBL] [Abstract][Full Text] [Related]
5. Clinical Acquired Resistance to KRAS Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136 [TBL] [Abstract][Full Text] [Related]
6. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321 [TBL] [Abstract][Full Text] [Related]
7. Ceddia S; Landi L; Cappuzzo F Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655 [No Abstract] [Full Text] [Related]
8. The KRAS-G12C inhibitor: activity and resistance. Liu J; Kang R; Tang D Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232 [TBL] [Abstract][Full Text] [Related]
10. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605 [TBL] [Abstract][Full Text] [Related]
11. A saturation mutagenesis screen uncovers resistant and sensitizing secondary Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904 [TBL] [Abstract][Full Text] [Related]
12. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy. Kirschner T; Müller MP; Rauh D J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359 [TBL] [Abstract][Full Text] [Related]
15. Nonclinical Safety Profile of Sotorasib, a KRAS Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282 [TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Reck M; Carbone DP; Garassino M; Barlesi F Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836 [TBL] [Abstract][Full Text] [Related]
17. Discoveries in the redox regulation of KRAS. Kramer-Drauberg M; Ambrogio C Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959 [TBL] [Abstract][Full Text] [Related]
18. KRAS mutation: from undruggable to druggable in cancer. Huang L; Guo Z; Wang F; Fu L Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511 [TBL] [Abstract][Full Text] [Related]
19. HER2 mediates clinical resistance to the KRAS Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459 [TBL] [Abstract][Full Text] [Related]
20. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]